Literature DB >> 20002689

Serious unconventional complications of surgery with stapler for haemorrhoidal prolapse and obstructed defaecation because of rectocoele and rectal intussusception.

G Naldini1.   

Abstract

AIM: Treatment of haemorrhoidal prolapse by stapled haemorrhoidopexy (SH) and obstructed defaecation syndrome with the stapled transanal rectal resection (STARR) technique is becoming increasingly popular with patients and surgeons. Unfortunately, serious complications have been identified. The aim of the present study was to analyse the complications and their treatment to see where they might be avoided and to determine best management.
METHOD: All Units of Coloproctology belonging to the Italian Unitary Society of Coloproctology (SIUCP) were asked to return documentation of serious complications following SH and STARR.
RESULTS: Forty-six reports were received from 23 centres. Twenty-seven serious complications were reported. Twenty occurred after SH (13 PPH 03, 7 PPH 01) (Endo-surgery Inc., Cincinnati, Ohio, USA) and seven after STARR. Complications were treated by abdominal operation in nine patients [colostomy (3), ileostomy (2), Hartmann's resection (1) and anterior resection (1)].
CONCLUSION: Stapled haemorrhoidopexy and STARR can result in serious complications requiring major surgery for their treatment.
© 2011 The Author. Colorectal Disease © 2011 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Mesh:

Year:  2011        PMID: 20002689     DOI: 10.1111/j.1463-1318.2009.02160.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  35 in total

Review 1.  Stapled haemorrhoidopexy: is it time to move on?

Authors:  E H Aly
Journal:  Ann R Coll Surg Engl       Date:  2015-08-14       Impact factor: 1.891

Review 2.  Functional Disorders: Rectocele.

Authors:  W Conan Mustain
Journal:  Clin Colon Rectal Surg       Date:  2017-02

3.  Sigmoid intramural hematoma and hemoperitoneum: an early severe complication after stapled hemorrhoidopexy.

Authors:  G De Santis; P Gola; L Lancione; F Sista; R Pietroletti; S Leardi
Journal:  Tech Coloproctol       Date:  2011-06-16       Impact factor: 3.781

4.  Resected specimen evaluation, anorectal manometry, endoanal ultrasonography and clinical follow-up after STARR procedures.

Authors:  Gabriele Naldini; Guido Cerullo; Claudia Menconi; Jacopo Martellucci; Simone Orlandi; Nicola Romano; Mauro Rossi
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

5.  Tailored prolapse surgery for the treatment of haemorrhoids and obstructed defecation syndrome with a new dedicated device: TST STARR Plus.

Authors:  Gabriele Naldini; Jacopo Martellucci; Roberto Rea; Stefano Lucchini; Michele Schiano di Visconte; Angelo Caviglia; Claudia Menconi; Donglin Ren; Ping He; Domenico Mascagni
Journal:  Int J Colorectal Dis       Date:  2014-02-26       Impact factor: 2.571

6.  Comments on stapled anopexy and STARR in surgical treatment of haemorrhoidal disease.

Authors:  Massimiliano Mistrangelo; Francesco Ghiglione; Paolo Tonello
Journal:  Updates Surg       Date:  2014-11-16

Review 7.  Documented complications of staple hemorrhoidopexy: a systematic review.

Authors:  Liesel J Porrett; Jemma K Porrett; Yik-Hong Ho
Journal:  Int Surg       Date:  2015-01

Review 8.  Management of obstructed defecation.

Authors:  Vlasta Podzemny; Lorenzo Carlo Pescatori; Mario Pescatori
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

9.  Short-term results after STARR versus internal Delorme for obstructed defecation: a non-randomized prospective study.

Authors:  N L Ohazuruike; J Martellucci; C Menconi; S Panicucci; G Toniolo; G Naldini
Journal:  Updates Surg       Date:  2014-01-16

10.  Long-term results after stapled hemorrhoidopexy: a survey study with mean follow-up of 12 years.

Authors:  A Sturiale; B Fabiani; C Menconi; D Cafaro; F Fusco; G Bellio; M Schiano di Visconte; G Naldini
Journal:  Tech Coloproctol       Date:  2018-10-04       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.